Resumen de: US2022304956A1

The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

Resumen de: US2022304959A1

Disclosed in certain embodiments is a method of treating long-haulers syndrome associated with infection (e.g., Covid-19) comprising administering a therapeutically effective amount of niclosamide or a pharmaceutically acceptable salt thereof to a patient in need thereof.

Resumen de: US2022304954A1

The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

Resumen de: US2022305145A1

Compositions and methods for the diagnosis and treatment of infectious diseases, including for the diagnosis and treatment of Cytokine Storm and Cytokine Release Syndrome. The compositions may include a conjugate of a nucleoside analog, a chelator, and a label for use as imaging and therapeutic agents.

Resumen de: US2022304947A1

The present invention discloses use of a composition comprising enriched in bisdemethoxycurcumin, specifically a composition comprising not less than 20% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% curcumin in preventing the activation of viral spike proteins by inhibiting the activity of proteolytic enzymes and in inhibiting the replication and growth of pathogenic viruses, specifically SARS-CoV-2 in mammalian cells. The invention also discloses the potential of the above composition in managing SARS-CoV-2 induced infections.

Resumen de: US2022307095A1

The present disclosure provides methods and systems for the massively-parallel detection of pathogens, such as SARS-CoV-2 virus, in a set of multiple samples via PCR test. Various implementations may provide for barcode/primer sequences that are designed to allow for a large number of samples and/or multiple pathogens to be analyzed in a single test. Included within the scope hereof are methods and systems for performing tests of multiple samples at once, via a one-pot test protocol, as well as methods and systems for designing test parameters (such as barcode/primer sequences) in a manner that allows for parallel testing.

Resumen de: EP4063865A1

The present discosure discloses a detection kit and a preparation method thereof and a detection method for novel coronavirus, and relates to the technical field of biomedicine, including antigen test strip; the antigen test strip includes a substrate, bibulous paper, immune nitrocellulose membrane, and immune microsphere pad; the immune microsphere pad, the immune nitrocellulose membrane and the bibulous paper are pasted on the substrate; the immune microsphere pad is coated with latex microsphere-labeled novel coronavirus SARS-CoV-2 monoclonal antibody 1; immune nitrocellulose membrane is provided with a test line coated with novel coronavirus SARS-CoV-2 monoclonal antibody 2 and a quality control line coated with goat anti-mouse IgG polyclonal antibody. The present disclosure uses latex particles as labeled tracer, and uses antigen-antibody reaction and lateral chromatography to detect and analyze targets, having advantages of convenience and swift, and is convenient to be widely carried out in grass-roots community hospitals and health service centers.

Resumen de: EP4063523A1

A composition for detecting SARS-CoV-2 is provided; moreover, a kit including the composition, the use of the kit, and a method for detecting SARS-CoV-2 are also provided.

Resumen de: EP4063384A1

The invention concerns antigen specific proteins, in particular antibodies of fragments thereof, specifically binding to RBD domain and interfering in the interaction of Spike protein with ACE2 receptor, said antigen specific proteins having neutralizing activity for SARS-CoV2 virus infection.

Resumen de: WO2021102210A1

Provided herein are methods, systems and devices for detecting a nucleic acid sequences and/or pathogens; including detecting the presence of absence of a target-nucleic acid sequences, including SARS-COV2.

Resumen de: EP4062930A1

La présente invention concerne une composition immunogène ou vaccinale contre le SARS-CoV-2, pour son utilisation dans le traitement de la Covid-19, caractérisée en ce qu'elle est administrée sur la muqueuse oculaire et/ou la muqueuse uro-génitale.

Resumen de: CA3148037A1

The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.

Resumen de: AU2021213137A1

Use of a class of ketoamide-based compounds, in particular, use of the ketoamide-based compound as represented by general formula A as a 2019 novel coronavirus (2019-nCov) 3CL protease inhibitor and/or human cathepsin L inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. The present invention also relates to use of pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection.

Resumen de: WO2022197255A1

The present invention demonstrates a recombinant vector for producing immunogenic substance from plants which can induce an immune response in mammals against the coronavirus disease 2019 (COVID-19). Said recombinant vector comprises at least a fragment of SARS Co V-2 receptor binding domain protein ( SARS Co V-2 RBD) and a fusion protein sequence. The recombinant vector is introduced into plant cells, preferrably by means of Agrobacterium sp., thereby the plant cell can express a recombinant protein which can act as an immunogenic substance. The recombinant protein of the present invention s igruficantly demonstrates an ability to trigger immunogenicity in mammals which prevents infectious disease caused by severe acute respirato1y syndrome coronavirus 2. Further, the method of inducing an immune response against SARS- Co V- 2 in mammals is also provided herein. The present invention further demonstrates the use of such recombinant protein as a vaccine to prevent the coronavirus disease 201 9 (COVID-1 9).

Resumen de: US2022296728A1

This disclosed technology relates to a new mRNA COVID-19 vaccine that is stable at room temperature, requires only one injection, and is less prone to patient hypersensitivity reactions. The vaccine is practical to deploy globally during vaccination campaigns for current and future coronavirus pandemics and other infectious diseases. The disclosed technology is a method and system for producing the vaccine, and also a double-encapsulated mRNA vaccine product. The method uses double nanoencapsulation of an mRNA vaccine, first in phospholipid nanosomes and then in biodegradable polymer nanospheres. The method may be carried out as a continuous flow, integral, or two-stage processes. The method and system use supercritical fluid technology for nanoencapsulating mRNA in a solvent free process that minimizes loss of potency and preserves antigenicity of the nanoencapsulated mRNA and eliminates residual organic solvents in the final product. The double-encapsulated mRNA vaccine product is stable at room temperature and can be administered in a single shot to humans.

Resumen de: US2022296700A1

A synthetic DNA vaccine against SARS-CoV-2 infection comprises a codon-optimized coding sequence for optimal mammalian expression of a pSARS2 spike glycoprotein (pSARS2-S). The signal peptide may be replaced with the signal peptide from the human IgG2 heavy chain. Systemic S1-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in mice at 2 weeks-post three injections with 100 μg of the pSARS2-S vaccine via intramuscular (IM) needle injection. IM immunization induced Th1-skewed and long-lasting IgG response in BALB/c mice. Immunogenicity and induction of nAbs were enhanced with a needle-free delivery system, wherein two doses were sufficient to elicit significant levels of systemic S1-specific IgG antibodies and nAbs via IM or intradermal immunization.

Resumen de: US2022296676A1

A method of treating or preventing a Coronaviridae infection in a subject comprising administrating a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the Coronaviridae comprises at least one selected from 2019-nCov virus, HCov 229E virus, SARS virus, MERS virus,

Resumen de: US2022299508A1

Provided herein, in some embodiments, are rapid diagnostic tests to detect one or more target nucleic acid sequences (e.g., a nucleic acid sequence of one or more pathogens). In some embodiments, the pathogens are viral, bacterial, fungal, parasitic, or protozoan pathogens, such as SARS-CoV-2 or an influenza virus. Further embodiments provide methods of detecting genetic abnormalities. Diagnostic tests comprising a sample-collecting component, one or more reagents (e.g., lysis reagents, nucleic acid amplification reagents), and a detection component (e.g., a component comprising a lateral flow assay strip) are provided.

Resumen de: US2022299506A1

The disclosure provides example devices and methods for making and using the devices for rapid testing for the SARS-CoV-2 virus. The example device includes (a) a substrate coupled to a metal oxide layer, (b) a graphene layer coupled to the metal oxide layer, (c) a chemical or biochemical linker functionalized with the graphene layer, and (d) a plurality of SARS-CoV-2 receptors that are bound to the graphene layer via the chemical or biochemical linker, wherein the plurality of SARS-CoV-2 receptors comprise SARS-CoV-2 spike antibodies or SARS-CoV-2 spike proteins, where the graphene layer is configured to have a first phononic energy, when the plurality of SARS-CoV-2 receptors are unattached to target molecules, and a second phononic energy, when the plurality of SARS-CoV-2 receptors are attached to target molecules.

Resumen de: WO2022197869A2

Up-regulation of caspase has been found in COVID-19 patients, and also occurs in patients suffering from diabetes, hypertension, metabolic syndrome, and other conditions. Such up-regulation can be responsible for poor clinical outcomes in patients having such diseases or disorders, as such up-regulation leads to a process called pyroptosis: death and malfunction of immune system cells, particularly of certain types of lymphocytes. An inhibitor of caspase such as a caspase 1 inhibitor, or "pan-caspase" inhibitor (i.e., an inhibitor of multiple caspase types including caspase-1), can be used to treat COVID-19 patients or individuals at risk of infection, by limiting the malfunction of the immune system. A caspase-1 or pan-caspase inhibitor is advantageously administered before or very early in the course of infection by a positive-sense, single-stranded RNA virus such as SARS-CoV, MERS-CoV, and SARS-Cov-2.

Resumen de: WO2022196699A1

Provided are follicular helper T cells specific to SARS-CoV-2 virus. On the basis of the discovery of a public Tfh TCR that is specific to a spike (S) protein common to various patients, the present disclosure identifies for the first time a SARS-CoV-2 virus-specific public TCR and the MHC and antigenic epitope thereof and thus promotes efficient immune responses, especially the response of B cells producing a neutralizing antibody. The present disclosure provides, for example, a SARS-CoV-2 virus-specific epitope-containing composition for inducing follicular T cells.

Resumen de: WO2022194296A1

Provided in the present invention is a detection device, which comprises a supporting plate, wherein a sample treatment pad, a reaction membrane and a water absorption pad are sequentially overlapped and adhered to the supporting plate from upstream to downstream, and a hydrophobic element is arranged at the downstream end of the water absorption pad of the detection device. The hydrophobic element, as a gripping area, can prevent further flow of a sample solution on the water absorption pad to an area, which is gripped by a user, of the detection device. The detection device of the present invention can effectively reduce the risk of infection of a user during sample inspection, especially the risk of infection of the user during sample inspection of infectious diseases, such as HBV, HIV, malaria, dengue fever, SARS and SARS-CoV-2.

Resumen de: WO2022195900A1

The present invention provides: a recombinant measles virus useful as a live vaccine against COVID-19; and a vector used for producing the recombinant measles virus. That is, the present invention is a recombinant measles virus in which a gene encoding a protein of corona virus SARS-CoV-2 is inserted between the N gene region and the P gene region in a measles virus gene; the recombinant measles virus in which the protein is the spike protein of SARS-CoV-2 or a partial protein thereof; and DNA in which a gene encoding a protein of SARS-CoV-2 is inserted into the region from the base at position 1686 to the base at position 1694 in the nucleotide sequence represented by SEQ ID NO: 2.

Resumen de: WO2022194286A1

The present invention provides a test combination packet and a test method for rapid sample test and analysis. The test combination packet comprises a test board and a sample extraction tube. The test combination packet and the test method provided by the present invention can improve the sensitivity of a product, play a positive role in suppressing the propagation of pathogens that cause respiratory diseases, and are suitable for rapid test of antigens and antibodies such as the currently popular novel coronavirus.

Resumen de: WO2022194136A1

The invention belongs to the technical field of medicine. A soluble berberine-type quaternary ammonium alkaloid compound and the use thereof in preparing a drug are disclosed. In particular, disclosed are a compound as represented by general formula A and a compound that further may be represented specifically by general formulas I and I', a pharmaceutical composition thereof, a preparation method therefor, and the use thereof. The compounds of the present invention have significant activity in treating cardiovascular, cerebrovascular and blood system diseases, inflammatory diseases, febrile diseases, tumor diseases, autoimmune diseases and viral infectious diseases and complications thereof by inhibiting/reducing the activity of biological body pathological NO, iNOS, IL-6 and autoantibody levels, and inhibiting the activity of SARS-COV 2 virus RNA replication. The strength of the physical and chemical properties as well as the pharmacological function of the compounds of the present invention are superior to those of control drugs and related compounds, and can be used for preparing drugs for preventing, alleviating and/or treating cardiovascular, cerebrovascular and blood system diseases, inflammatory diseases, febrile diseases, tumor diseases, autoimmune diseases and viral infection diseases and complications thereof.